Related Experiment Video

Updated: Jun 23, 2026

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure
08:40

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

7.6K

Establishing a pediatric reference interval for plasma calprotectin

Anne-Birgitte Garm Blavnsfeldt1, Tina Parkner1, Cindy Soendersoe Knudsen1

  • 1Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

Scandinavian Journal of Clinical and Laboratory Investigation
|April 13, 2024
PubMed

Insights

This study establishes the first pediatric reference interval for plasma calprotectin, a key inflammatory biomarker, using the Phadia 250 assay. The findings provide crucial data for diagnosing inflammatory conditions in children and adolescents.

Area of Science:

  • Biochemistry
  • Pediatric Medicine
  • Clinical Diagnostics

Background:

  • Plasma calprotectin is a valuable biomarker for inflammatory activity in pediatric inflammatory bowel disease.
  • A validated pediatric reference interval for plasma calprotectin using the Phadia 250 EliA™ Calprotectin assay is currently lacking.
  • Pre-analytical studies show good precision and stability, but highlight sensitivity to hemolysis.

Purpose of the Study:

  • To establish a pediatric reference interval for plasma calprotectin using the Phadia 250 EliA™ Calprotectin fluoroenzyme immunoassay.
  • To provide a benchmark for interpreting plasma calprotectin levels in children and adolescents.
  • To support the clinical utility of plasma calprotectin as an inflammatory marker in pediatric populations.

Main Methods:

  • Identification of 141 pediatric blood samples from apparently healthy children.
  • Exclusion criteria included recent blood sampling, abnormal hemoglobin (Hb) or C-reactive protein (CRP) levels, and significant hemolysis.
  • Application of Clinical and Laboratory Standards Institute (CLSI) C28-A3 guidelines with non-parametric statistical analysis.

Main Results:

  • A reference interval for plasma calprotectin was established for children aged 1-17 years as 16-246 µg/L.
  • No statistical outliers were identified in the selected pediatric sample cohort.
  • The established reference interval adheres to CLSI guidelines for diagnostic testing.

Conclusions:

  • The study successfully established a pediatric reference interval for plasma calprotectin using the Phadia 250 assay.
  • This reference interval is essential for accurate interpretation of plasma calprotectin in pediatric inflammatory conditions.
  • The findings facilitate the broader use of plasma calprotectin as a reliable inflammatory marker in children and adolescents.

Keywords:
Calprotectininflammationpediatricsplasmareference values

More Related Videos

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

2.6K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

582

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...